These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27687015)

  • 1. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Role for Newly Approved Iron Treatments.
    Fishbane S
    Semin Dial; 2017 Jan; 30(1):27-29. PubMed ID: 27687015
    [No Abstract]   [Full Text] [Related]  

  • 2. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Emerging Evidence on the Safety of Intravenous Iron in Chronic Kidney Disease.
    Agarwal R
    Semin Dial; 2017 Jan; 30(1):22-25. PubMed ID: 27678472
    [No Abstract]   [Full Text] [Related]  

  • 3. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.
    Alan Brookhart M; Li X; Kshirsagar AV
    Semin Dial; 2017 Jan; 30(1):25-27. PubMed ID: 27766683
    [No Abstract]   [Full Text] [Related]  

  • 4. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Benefits of Intravenous Iron.
    Wish JB
    Semin Dial; 2017 Jan; 30(1):20-22. PubMed ID: 27679413
    [No Abstract]   [Full Text] [Related]  

  • 5. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.
    Besarab A; Szczech L
    Semin Dial; 2017 Jan; 30(1):29-31. PubMed ID: 27699882
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous iron therapy in non-dialysis CKD patients.
    Macdougall IC
    Nephrol Dial Transplant; 2014 Apr; 29(4):717-20. PubMed ID: 24319013
    [No Abstract]   [Full Text] [Related]  

  • 7. More than a decade of experience and still no consensus: controversies in iron therapy.
    Besarab A
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S1-3. PubMed ID: 17699371
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron therapy for managing anaemia in chronic kidney disease.
    Macdougall IC
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):358-363. PubMed ID: 29905580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.
    Fishbane S
    Semin Nephrol; 2016 Mar; 36(2):119-23. PubMed ID: 27236133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron therapy in chronic kidney disease: Recent changes, benefits and risks.
    Ribeiro S; Belo L; Reis F; Santos-Silva A
    Blood Rev; 2016 Jan; 30(1):65-72. PubMed ID: 26342303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease.
    Aksan A; Farrag K; Stein J
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):95-97. PubMed ID: 30791779
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous iron treatment in general practice.
    ISAACS B
    Practitioner; 1952 Jul; 168(1009):67-71. PubMed ID: 14948760
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-intravenous approaches to iron therapy in chronic kidney disease: will it improve the benefit-to-risk ratio?
    Besarab A
    Nephrol News Issues; 2014 Feb; 28(2):12, 14-5. PubMed ID: 24649747
    [No Abstract]   [Full Text] [Related]  

  • 14. Iron Treatment Strategies in Nondialysis CKD.
    Macdougall IC
    Semin Nephrol; 2016 Mar; 36(2):99-104. PubMed ID: 27236130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heme iron polypeptide for the management of anaemia of chronic kidney disease.
    Dull RB; Davis E
    J Clin Pharm Ther; 2015 Aug; 40(4):386-90. PubMed ID: 25953602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the safety of intravenous iron treatments for patients with chronic kidney disease.
    Kassianides X; Hazara AM; Bhandari S
    Expert Opin Drug Saf; 2021 Jan; 20(1):23-35. PubMed ID: 33203251
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
    Rottembourg J; Rostoker G
    Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic reactions due to intravenous iron.
    LIBRACH IM
    Br Med J; 1953 Jan; 1(4800):21-4. PubMed ID: 12997822
    [No Abstract]   [Full Text] [Related]  

  • 19. [Iron therapy in chronic kidney disease].
    Graczyk M; Kohmann A
    Wiad Lek; 2016; 69(5):749-752. PubMed ID: 28033601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease.
    Zager RA
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S24-31. PubMed ID: 17699373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.